Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 1 Results

  1. 1

    Glaxo's AZT announcement welcomed, but detail is yet to follow. mother-to-child transmission.

    Worthington H

    AIDS ANALYSIS AFRICA. 1998 Apr; 8(2):2.

    Following recently completed trials of AZT in Thailand among pregnant women which showed that a short course of AZT can significantly reduce the mother-to-child transmission of HIV, Glaxo Wellcome recently announced that it will supply the antiretroviral drug AZT at a preferential price for pregnant women infected with HIV in developing countries. Since the size of the HIV/AIDS epidemic and the quantity of AZT needed cannot be predicted, Glaxo Wellcome has stated that it is unfeasible to implement a mass donation program of the drug. The preferential public sector pricing was instead arrived at after 3 years of discussions and collaboration with UNAIDS, governments, and nongovernmental organizations (NGOs). Glaxo and UNAIDS both agree that the pricing will be a price reduction and not a subsidy, but additional details remain unclear. Eligible countries will be defined according to World Health Organization guidelines, with UNICEF likely to play a key role in the AZT's distribution.
    Add to my documents.